Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin subunit beta 3 (ITGB3)
- Target
- ITGB3
- Molecular classification
- Integrin subunit, Receptor
01
Overview
Integrin subunit beta 3 (ITGB3), also known as CD61, is a protein encoded by the ITGB3 gene in humans. It is a critical component of several integrin receptors, including αIIbβ3 (GPIIb/IIIa) and αVβ3, and plays essential roles in cell adhesion, signaling, and hemostasis. Mutations in ITGB3 can cause Glanzmann thrombasthenia, a bleeding disorder. It interacts with several proteins, including PTK2, TLN1, and CIB1, and binds to ligands such as fibrinogen, vitronectin, and fibronectin via R-G-D motifs.
- Other names
- CD61GP3AGPIIIaPlatelet glycoprotein IIIaVitronectin receptor beta chain
02
Mechanism of action
Integrin antagonism (drugs that bind to ITGB3 can prevent ligand binding and subsequent platelet aggregation or cell adhesion)
03
Biological functions
Cell adhesionCell signalingHemostasisPlatelet aggregationWound healingSynaptic function
04
Disease associations
Glanzmann ThrombastheniaEndometriosisOsteopetrosisBleeding disorders
05
Safety considerations
Potential for bleeding complications with integrin antagonists
06
Biomarkers
Expression levels in endometriosis diagnosis
Beyond the preview
Go deeper on Integrin subunit beta 3 (ITGB3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Integrin subunit beta 3 (ITGB3).